Form 4: Gilead Sciences' Chief Medical Officer, Merdad Parsey, Reports Stock Transactions

Merdad Parsey, Chief Medical Officer of Gilead Sciences, reports the acquisition and disposal of common stock and restricted stock units on June 10, 2024.

Summary

• On June 10, 2024, Merdad Parsey, the Chief Medical Officer of Gilead Sciences, engaged in transactions involving the company's stock.
• Parsey acquired 3,820 shares of common stock through the vesting of restricted stock units.
• He also disposed of 1,744 shares of common stock at a price of $65.25 per share.
• Following these transactions, Parsey directly owns 98,380 shares of Gilead Sciences common stock.
• He also holds 44,394 restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard regulatory filing reporting stock transactions. There's no indication of positive or negative sentiment towards the company's performance.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It allows investors to monitor the actions of key executives like the Chief Medical Officer and assess their confidence in the company's prospects.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the trading activities of a key executive.
• It can influence investor perception, although individual Form 4 filings typically have a limited direct impact unless they indicate a significant trend.

Key Dates